Evidence-based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis
Open accessAbstract
Recurrent vulvovaginal candidiasis (RVVC) is a subtype of vulvovaginal candidiasis, with debilitating effects on physical and emotional well-being affecting up to 10% of Australian women. Current evidence suggests that the induction and maintenance approach for RVVC is not particularly effective with post-treatment relapse rates as high as 57%. Frequently accessed Australasian RVVC prescribing resources and guidelines were examined showing a variety of adaptations of current evidence-based induction and maintenance therapies, making it difficult to select best treatment in clinical practice. The ways to introduce more clarity and consistency into these guidelines are outlined.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The literature suggests that RVVC can frequently feature culture negative symptomatic episodes.
“In addition, the literature suggests that RVVC can frequently feature culture negative symptomatic episodes.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Bradfield Strydom et al., 2021
Guidelines that focus only on a positive culture may not provide optimal care options for all patients, especially for those experiencing frequent recurrences.
“Thus, the guidelines that focus only on a positive culture may not provide optimal care options for all patients, especially for those experiencing frequent recurrences (Bradfield Strydom et al., 2021).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Bradfield Strydom et al., 2021
Cites
Global burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639 · see citing works
Fluconazole resistance in <em>Candida</em> species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542 · see citing works
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487 · see citing works
Probiotics for vulvovaginal candidiasis in non-pregnant women
Xie, H. Y., Feng, D., Wei, D. M., Mei, L., Chen, H., Wang, X., & Fang, F. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010496.pub2 · Cited by 129 · see citing works
Donders, G., Bellen, G., Byttebier, G., Verguts, L., Hinoul, P., Walckiers, R., Stalpaert, M., Vereecken, A., & Van Eldere, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.029 · Cited by 127 · see citing works
Use of Oral Fluconazole during Pregnancy and the Risk of Birth Defects
Mølgaard‐Nielsen, D., Pasternak, B., & Hviid, A. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301066 · Cited by 121 · see citing works
Vulvovaginal Candidiasis as a Chronic Disease
Hong, E. S., Dixit, S., Fidel, P. L., Bradford, J. A., & Fischer, G. O. (2013) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e318287aced · Cited by 69 · see citing works
Recurrent vulvovaginal candidiasis: A review of guideline recommendations
Matheson, A., & Mazza, D. (2017) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12592 · Cited by 68 · see citing works
Treatment of Non-Albicans Candida Vaginitis with Amphotericin B Vaginal Suppositories
Phillips, A. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.034 · Cited by 66 · see citing works
Watson, C. J., & Calabretto, H. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00736.x · Cited by 65 · see citing works
Collins, L. M., Moore, R., & Sobel, J. D. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000496 · Cited by 55 · see citing works
Powell, A. M., Ghanem, K. G., Rogers, L. C., Zinalabedini, A., Brotman, R. M., Zenilman, J. M., & Tuddenham, S. (2019) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001063 · Cited by 36 · see citing works
The Role of Diagnostic Stewardship in Clostridioides difficile Testing: Challenges and Opportunities
Boly, F., Reske, K. A., & Kwon, J. H. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0715-4 · Cited by 34 · see citing works
Successful Treatment of Refractory Recurrent Vaginal Candidiasis with Cetirizine Plus Fluconazole
Neves, N. A., Carvalho, L. P., Lopes, A. C. V., et al. (2005) · Journal of Lower Genital Tract Disease · doi:10.1097/01.lgt.0000171664.63976.fb · Cited by 27 · see citing works
Nguyen, Y., Lee, A., & Fischer, G. (2017) · Australasian Journal of Dermatology · doi:10.1111/ajd.12487 · Cited by 25 · see citing works
Management of chronic vulvovaginal candidiasis: a long term retrospective study
Nguyen, Y., Lee, A. C.-Y., & Fischer, G. O. (2016) · Australasian Journal of Dermatology · doi:10.1111/ajd.12497 · Cited by 16 · see citing works
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis
Story, K., & Sobel, R. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0712-7 · Cited by 16 · see citing works
Recurrent vulvovaginal candidiasis - current management.
Watson, C. J., & Pirotta, M. V. (2011) · PubMed · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82 · see citing works
- Authors
- Bradfield Strydom, M., Walpola, R. L., Khan, S., Ware, R. S., & Tiralongo, E.
- Affiliations
- School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia
- UNSW Sydney (AU)
- Griffith University (AU)
- Corresponding author
- Tiralongo, Evelin
- Venue
- Australian and New Zealand Journal of Obstetrics and Gynaecology
- Publisher
- Wiley
- Published
- 2021-06-03
- Volume
- 61
- Issue
- 4
- Pages
- 496-499
- ISSN
- 0004-8666 (ISSN-L)
- 1479-828X
- OpenAlex
- W3165658062
- Cited by
- 5
- References
- 18
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 2
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Australian and New Zealand Journal of Obstetrics and Gynaecology (publishedVersion)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- recurrent vulvovaginal candidiasis, antifungal prescribing, induction therapy, maintenance therapy, treatment relapse, guideline consistency
- MeSH terms
- Antifungal Agents, Australia, Candidiasis, Vulvovaginal, Chronic Disease, Pharmaceutical Preparations, Female, Humans, Recurrence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
